A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Phase 2TerminatedNCT01904253

Taiho Oncology, Inc.18 enrolled

Overview

The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease progression, and the safety of TAS-102.

This is a multicenter, open-label, two-arm, randomized Phase 2 study of TAS-102 versus Investigator's choice of therapy in patients requiring second-line chemotherapy for SCLC refractory or sensitive to first-line platinum-based chemotherapy. Investigator's choice of therapy is defined as second-line chemotherapy with IV topotecan (Europe/Japan) or IV amrubicin (Japan). Patients will be stratified by response to first-line platinum-based chemotherapy (sensitive vs refractory). Sensitive patients are defined as patients who did not progress within 90 days after the last dose, and refractory patients are defined as patients who never responded or who responded but had radiologic progression \< 90 days after the last dose.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

TAS-102DRUG

35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Amrubicin (Japan)DRUG

Patients will receive treatment administered according to the country-specific approved prescribing information

Topotecan (Japan/Europe)DRUG

Patients will receive treatment administered according to the country-specific approved prescribing information

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Has provided written informed consent 2. Is ≥18 years of age for patients enrolled in Europe; or ≥20 years of age for patients enrolled in Japan 3. Has definitive histologically or cytologically confirmed SCLC (limited or extensive disease) 4. Has progressed or had recurrence within 30 days prior to randomization 5. Has at least one measurable lesion, as defined by RECIST criteria version 1.1 6. ECOG performance status of 0, 1, or 2 7. Is able to take medications orally 8. Has adequate organ function (bone marrow, kidney and liver) 9. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control. Exclusion Criteria: 1. Has cerebral metastases (unless metastases have been treated and controlled, metastases have been stable for at least 2-months post-intervention, and patient is not receiving corticosteroid treatment) 2. Certain serious illnesses or medical condition(s) 3. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration 4. Has received TAS-102 5. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies 6. Is a pregnant or lactating female

Locations (23)

Klinikum Mannheim GmbH Universitaetsklinikum

Mannheim, Baden-Wurttemberg, Germany

Outcomes

Primary Outcomes

Progression-free survival

Tumor assessments will be performed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 every 6 weeks during study treatment, and every 8 weeks after treatment is completed. Tumor assessments will be performed from Day 1, Cycle 1 until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.

Time frame: Every 6 weeks from the start of study treatment (Day 1, Cycle 1). Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment.

Secondary Outcomes

Overall survival

Time frame: Survival status will be collected at 8-week intervals until death, for up to 12 months after the first dose of study medication for the last patient randomized or until the target number of events (deaths) is met, whichever is later.

Safety monitoring including adverse events, vital signs, and laboratory assessments

Standard safety monitoring will be performed and adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

Time frame: Through 30 days following last administration of study medication or until initiation of new anticancer treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.